来自一项全球观察研究的两年瑞士队列结果,该研究调查了在神经血管与年龄相关的黄斑退化症中使用2毫克肠内阿弗利塞普特的积极剂量
Katja Hatz1,2, Aude Ambresin3,4, Martin Schmid5,6
1Vista Eye Clinic Binningen, Hauptstrasse 55, 4102 Binningen, Switzerland.
Journal of clinical medicine
|April 12, 2025
概括
在瑞士进行的XTEND研究发现,在24个月内,用静脉内阿弗利塞普特 (IVT-AFL) 进行主动治疗,改善了新血管年龄相关黄斑变性 (nAMD) 患者的视力和减少了视网膜厚度. 这些现实数据支持IVT-AFL.
科学领域:
- 眼科医生 眼科 眼科
- 视网膜疾病 视网膜疾病
- 药理疗法 药理疗法 药理疗法
背景情况:
- XTEND研究是一项大型的,全球性的,前性的观察性研究倡议.
- 它专注于以前没有接受过治疗的被诊断为患有新血管与年龄相关的黄斑变性 (nAMD) 的患者.
- 这项研究调查了2毫克静脉内阿弗利塞普特 (IVT-AFL) 在常规临床环境中的实际有效性.
研究的目的:
- 报告XTEND研究中瑞士队列的结果.
- 评估使用IVT-AFL 2 mg在nAMD患者中的积极治疗方案的实际有效性.
- 评估视觉和解剖结果,治疗暴露和24个月的安全性.
主要方法:
- 符合条件的患者年龄在50岁或以上,计划接受IVT-AFL 2毫克治疗.
- 在最初的三个月度IVT-AFL注射后,治疗间隔可以延长,最少间隔4周.
- 视力敏度,中心子场厚度,治疗频率和安全性都被监测和描述性地分析.
主要成果:
- 51名患者被纳入瑞士队列.
- 在24个月后,平均最佳校正视敏度 (BCVA) 从基线改善了+5.6个字母,中央子场厚度 (CST) 减少了-127微米.
- 在高基线BCVA (≥70个字母) 的患者中,视力保持良好,CST在24个月内显著减少.
- 患者在24个月内平均接受了13.7次注射,没有发现安全问题.
结论:
- 在瑞士常规临床实践中,用2毫克IVT-AFL主动治疗导致24个月的nAMD患者的功能和解剖改善.
- 这些积极的结果甚至在具有相对较高的基线视力敏度的患者中也被观察到.
- 这些发现支持了针对nAMD管理的积极IVT-AFL治疗策略的实际有效性.
关键词:
瑞士 瑞士 瑞士 瑞士 瑞士 瑞士 瑞士抗血管内皮生长因子的抗血管内皮生长因子临床试验临床试验临床试验临床试验临床试验体内外的自由接收新血管与年龄相关的黄斑变性.这是一个观察性的观察.现实世界的证据.视网膜 视网膜 视网膜 是一个视觉 视觉 视觉 视觉 是一个更多相关视频
08:54Author Spotlight: Understanding Age-Related Macular Degeneration Pathophysiology with QAF Workflow
Published on: May 26, 2023
1.3K
05:14Author Spotlight: Overcoming Anti-VEGF Resistance Through Advanced Vascular Morphology Assessment in Choroidal Neovascularization
Published on: August 11, 2023
976
相关概念视频
01:25Glaucoma: Overview
1.7K
Glaucoma is an eye condition characterized by increased intraocular pressure that damages the retina and optic nerve, leading to irreversible blindness if left untreated. The human eye has various components, including the cornea, iris, pupil, lens, and optic nerve. Aqueous humor is secreted by the epithelium of the ciliary body in the posterior chamber and flows through the trabecular meshwork and canal of Schlemm, maintaining normal intraocular pressure. The trabecular meshwork and the canal...
1.7K
01:27Open Angle Glaucoma: Treatment
1.1K
In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
Drugs such as carbonic anhydrase inhibitors, α2- and...
1.1K
01:28Angle Closure Glaucoma: Treatment
1.7K
Angle-closure glaucoma, or closed-angle glaucoma, is an eye condition where the iris bulges out and blocks the iridocorneal angle, resulting in a buildup of aqueous humor and increased intraocular pressure. Immediate medical attention is necessary due to the sudden onset of symptoms. The treatment for angle-closure glaucoma includes short-term and long-term approaches. Short-term treatment involves using eye drops like pilocarpine to lower intraocular pressure by increasing aqueous humor...
1.7K
01:27Diabetic Retinopathy
65
DefinitionDiabetic retinopathy is a microvascular complication of diabetes affecting the retinal blood vessels.Risk FactorsDiabetic retinopathy is present in almost all individuals with type 1 diabetes and more than 60% of those with type 2 diabetes after two decades of disease.The risk increases with poor glycemic control, hypertension, dyslipidemia, smoking, pregnancy, and puberty.Although cataracts and glaucoma are also more frequent in people with diabetes, retinopathy remains the leading...
65